Clinical Pharmacokinetics of Paraaminosalicylic Acid Tablets
Abstract
Pharmacokinetic parameters of PAS-Akri coated tablets (Akrikhin, Russia) were investigated. The tablets contain paraaminosalicylic acid (PAS) as sodium dihydrate in an amount of 1000 mg. The single oral dose of the drug for healthy volunteers in the trial was 6, 9 or 12 tablets. In 7 days the dosage was changed. The blood samples were collected 0.25, 0.5, 0.75, 1, 2, 4, 6, 8 and 10 hours after the drug administration. The PAS serum levels were determined with HPLC. The trials will allow to optimize the dosing of PAS for providing efficient antituberculosis therapy.
About the Authors
I. I. Miroshnichenko
Scientific Centre of Mental Health, Russian Academy of Medical Sciences, Moscow; Research Institute of Phthisiology and Pulmonologyry, I.M. Sechenov Moscow Medical Academy, Moscow; Akrikhin Co., Moscow
Russian Federation
Russian Federation
G. B. Sokolova
Scientific Centre of Mental Health, Russian Academy of Medical Sciences, Moscow; Research Institute of Phthisiology and Pulmonologyry, I.M. Sechenov Moscow Medical Academy, Moscow; Akrikhin Co., Moscow
Russian Federation
Russian Federation
L. V. Mokhireva
Scientific Centre of Mental Health, Russian Academy of Medical Sciences, Moscow; Research Institute of Phthisiology and Pulmonologyry, I.M. Sechenov Moscow Medical Academy, Moscow; Akrikhin Co., Moscow
Russian Federation
Russian Federation
References
1. Iseman M.D. Tuberculosis therapy: past, present and future. // Eur. Respir. J 2002; 36: 87-94.
2. Wilson J.W., Kelkar P., Frigas E. Para-aminosalicylic acid (PAS) desensitization review in a case of multidrug-resistant pulmonary tuberculosis. // Int J Tuberc Lung Dis 2003; 7 (5): 493-497.
3. Glazko A.J. Early adventures in drug metabolism: 2. The absorption of drugs. // Ther Drug Monit. 1987; 9 (2): 180-189.
4. Hughes N.C., Janezic S.A., McQueen K.L. et al. Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in vivo and in vitro probe. Pharmacogenetics. 1998; 8 (1): 55-66.
5. Peloquin C.A., Zhu M., Adam R.D., Singleton M.D., Nix D.E. Pharmacokinetics of para-aminosalicylic acid granules under four dosing conditions. // Ann Pharmacother 2001; 35: 1332-1338.
6. Vasbinder E., Van der Weken G., Vander Heyden Y. et al. Quantitative determination of p-aminosalicylic acid and its degradation product m-aminophenol in pellets by ion-pair high-performance liquid chromatography applying the monolithic Chromolith Speedrod RP-18e column. // Biomed Chromatogr 2004; 18 (1): 55-63.
7. Мирошниченко И.И. Основы фармакокинетики. М: ГЭОТАР-МЕД 2002. 192.
8. Laub P.B., Gallo J.M. NCOMP a Windows-based computer program for noncompartmental analysis of pharmacokinetic data. // J. Pharmaceut. Sci. 1996; 85: 4: 393-395.
9. Schlatter J., Di Blasi-Bouvet S., Raynaud F., Cisternino S. Population pharmacokinetics of methotrexate in the guinea pig. // Cell Mol Biol 1999. 30; 3: 363-368.
Review
For citations:
Miroshnichenko I.I., Sokolova G.B., Mokhireva L.V. Clinical Pharmacokinetics of Paraaminosalicylic Acid Tablets. Antibiot Khimioter = Antibiotics and Chemotherapy. 2009;54(1-2):20-24. (In Russ.)
Views:
413
Email this article 